Background In the 5 years that have passed since the publication of the 2018 International
Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR‐Allergic Rhinitis …

Systemic lupus erythematosus (SLE) is a chronic multifactorial autoimmune disease that
affects many organs, including the kidney. Lupus nephritis (LN) is a common manifestation …

Objectives To characterise the efficacy and safety of anifrolumab in patients with systemic
lupus erythematosus (SLE) according to interferon gene signature (IFNGS), demographic …

Kidney involvement in patients with systemic lupus erythematosus—lupus nephritis (LN)—is
one of the most important and common clinical manifestations of this disease and occurs in …

Systemic lupus erythematosus (SLE) is a genetically predisposed, female-predominant
disease, characterized by multiple organ damage, that in its most severe forms can be life …

The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway
serves as a paradigm for signal transduction from the extracellular environment to the …

Treatment of systemic lupus erythematosus (SLE) currently employs agents with relatively
unselective immunosuppressive properties. However, two target-specific biological drugs …

Objectives In the anifrolumab systemic lupus erythematosus (SLE) trial programme, there
was one trial (TULIP-1) in which BILAG-based Composite Lupus Assessment (BICLA) …

Background and Objectives Recently accumulating evidence suggests the pivotal role of
type 1 interferon (IFN-1) signature in the pathogenesis of neuromyelitis optica spectrum …

Objective To determine the safety and efficacy of anifrolumab in patients with systemic lupus
erythematosus (SLE) classified based on the Lupus Low Disease Activity State (LLDAS) in …